Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.
| Website | http://tessellatebio.com/ |
| Revenue | $5.8 million |
| Employees | 27 (14 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Drug Development, Precision Oncology, Cancer Biomarkers, Cancer Therapeutics, Personalized Medicine, Novel Medicines, Biotechnology, Drug Discovery, Cancer Research, Oncology Drugs, Pharmaceutical Research, Clinical Stage, Preclinical Development, Cancer Treatment, Targeted Therapy, Biopharmaceutical, Life Sciences, Medicinal Chemistry, Molecular Biology |
| Competitors | Appia Bio, Alveo Technologies, CureMetrix, Diverse Biotech, Genomatix AG, BioNano, Twist Bioscience, Zymergen, Inc., Synthego Corporation, Codexis, Inc. +35 more (view full list) |
Looking for a particular Tessellate BIO employee's phone or email?
Tessellate BIO Questions
The Tessellate BIO annual revenue was $5.8 million in 2026.
Andree Blaukat is the CEO of Tessellate BIO.
14 people are employed at Tessellate BIO.
Top Tessellate BIO Employees
-
1
-
21
-
1
-
Corné van Den Kieboom
Discovery leader at Tessellate BIO
Amsterdam, NH, NL3 -
Ana Alias
Head of Finance at Tessellate BIO
Cambridge, Cambridgeshire, United Kingdom1 -
1
-
Nick Martin
Medicinal Chemistry Lead at Tessellate BIO
United Kingdom21 -
Jana Wolf
Senior Discovery Leader at Tessellate BIO
Cambridge, Cambridgeshire, United Kingdom11 -
1
-
Nelma Palminha
Senior Scientist at Tessellate BIO
United Kingdom1
